Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Seres Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 63 | 1 | 33 | −29 |
| SharesConverted for a 1-for-20 split | 3.08M | 17.25 | 2.28M | −790.1K (−25.7%) |
| Value | $43.1M | $242 | $25.4M | −$17.7M (−41.0%) |
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Seres Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 91,405 | $1.02M | 0.00% |
| XTX Topco Ltd | 22,417 | $249.1K | 0.01% |
| Squarepoint Ops LLC | 20,908 | $232.3K | 0.00% |
| Atlantic Union Bankshares Corp | 411 | $4.57K | 0.00% |
| Tower Research Capital LLC (TRC) | 185 | $2.06K | 0.00% |
| UMA Financial Services, Inc. | 142 | $1.58K | 0.00% |
| Raymond James Financial Inc | 56 | $623 | 0.00% |
| US Bancorp | 25 | $278 | 0.00% |
Sold out (37)
Institutions that held Seres Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (1)
Institutions that held Seres Therapeutics, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Sandy Spring Bank | 345 | $242 |